摘要
肺癌是目前我国发病率和死亡率最高的恶性肿瘤之一,早期肺癌患者多无明显症状,而约60%的肺癌患者在初诊时即有远处转移,晚期患者5年生存率不高。因此,临床亟需可用于肺癌早期筛查和诊断、个体化治疗监测、预后评估及耐药监测等方面的新兴肿瘤标志物。相较于传统的组织活检,液体活检因其无创、样本易获得、重复性高、可反映肿瘤的整体状态等优势,能够实现对肿瘤实时监测,已成为近年研究的热点。本文就液体活检在肺癌临床诊疗中的应用作一综述。
Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths in China.Most patients with early lung cancer have no obvious symptoms,while about 60%of lung cancer patients have distant metastasis when they are first diagnosed.The 5-year survival rate of advanced patients is not high.Therefore,there is an urgent need for lung cancer biomarkers that can be used for early screening and diagnosis,individualized treatment monitoring,prognosis assessment and drug resistance monitoring.Liquid biopsy has become an emerging research hotspot of attention compared to traditional tissue biopsy because of some of its advantages.They are nontraumatic,easy to obtain,reflect the overall state of the tumor,and allow for real-time dynamic monitoring.This article reviews the clinical application of liquid biopsy in lung cancer.
作者
陈长强
马丽芳
王佳谊
CHEN Chang-qiang;MA Li-fang;WANG Jia-yi(Department of Clinical Laboratory Medicine,Shanghai Chest Hospital,Shanghai 200030,China)
出处
《实用医院临床杂志》
2023年第5期18-21,共4页
Practical Journal of Clinical Medicine
作者简介
王佳谊,男,博士,研究员,博士生导师。国家优秀青年科学基金获得者,上海市青年科技启明星,上海市卫生系统优秀青年,上海市卫生系统银蛇奖二等奖。中国抗癌协会青年理事,中华医学会检验医学分会青年教师科创联盟主席团成员,上海市医学会检验医学分会委员。研究方向:肿瘤发病机制及相关标志物开发。
